Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highlyaltered genome: combined molecular and therapeutic studies

Autor: Farre, L, Sanz, G, Ruiz-Xiville, N, de Moura, MC, Martin-Tejera, JF, Goncalves-Ribeiro, S, Martinez-Iniesta, M, Calaf, M, Mosquera, JL, Martin-Subero, JI, Granada, I, Esteller, M, Domingo-Domenech, E, Climent, F, Villanueva, A, Sureda, A

Publikováno v: DISEASE MODELS & MECHANISMS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::756228ed8b66ee46b7077350e3f12836
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4168

Orthotopic xenografts models in relapse/refractory lymphomas: a preclinical model for therapeutic, mechanistic and functional studies.

Autor: Domenech, E. Domingo, Climent, F., Barca, E. Gonzalez, de Lama, E., Lopez‐Pereira, P., Martinez‐Iniesta, M., Calaf, M., Oliveira, A., Montaner, C., Aguilera, C., Banda, E. de la, Villanueva, A., Sureda, A., Farre, L.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p551-552, 2p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MA23.02 CDK4/6 Inhibitors Show Antitumor Effects in Preclinical Models of Malignant Pleural Mesothelioma

Autor: Aliagas, E., Martínez-Iniesta, M., Hernández, M., Alay, A., Cordero, D., Solé, X., Rivas, F., Ureña, A., Vilariño, N., Muñoz-Pinedo, C., Villanueva, A., Nadal, E.

Publikováno v: In Journal of Thoracic Oncology October 2019 14(10) Supplement:S343-S343

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.